Cerebral Amyloid Imaging Using Florbetapir (AV-45) — IDEA3  

Dementia Clinical Trial

Official title: Cerebral Amyloid Imaging Using Florbetapir (18F-AV-45) for the Etiological Diagnosis of Poststroke Cognitive Impairment and Dementia

Status Recruiting

Clinical Trial Summary

This study is aimed at examining the interest of amyloid radiotracer Florbetapir (18F-AV-45) for the etiological diagnosis of poststroke cognitive impairment and dementia

Clinical Trial Description

This study is aimed at examining the interest of amyloid radiotracer Florbetapir (18F-AV-45) for the etiological diagnosis of poststroke cognitive impairment and dementia. This study stems from two converging objectives: (1) the need to refine characteristics of vascular cognitive impairment (VCI) and dementia (VD) in order to propose diagnosis criteria of VCI and of mixed dementia and to improve diagnosis criteria of VD and (2) the need to improve the etiological diagnosis of poststroke cognitive impairment and dementia. It will take advantage from the ongoing GRECOG-VASC study (which determines the cognitive status 6 months poststroke in consecutive patients according to a standardized international battery) coordinated by the Amiens University Hospital center, the opportunity to perform amyloid imaging in vivo using Positron Emission Tomography (PET) and Florbetapir (a production site is located in the city of Amiens) and the collaboration between neurology and imaging departments of Amiens University hospital. ;

Related Conditions & MeSH terms

• Cognition Disorders
• Dementia

• NCT number: NCT02813434
• Study type: Interventional
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Olivier Godefroy, MD, PhD
• Phone: +33 3 22 66 84 47
• Email: godefroy.olivier@chu-amiens.fr
• Status: Recruiting
• Phase: Phase 3
• Start date: September 2014
• Completion date: September 2022